CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for G2GBio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

G2GBio Inc
21
Uiryodanji-gil, Osong-eup, Heungdeok-gu
Phone: +82 432706000p:+82 432706000 CHEONGJU, 28161  South Korea Fax: +82 432706099f:+82 432706099
Business Summary
G2GBio Inc is a Korea-based company principally engaged in the development of long-acting pharmaceutical formulations. The Company is mainly engaged in the development of long-acting pharmaceutical products, including pipeline candidates such as GB-7001 (for diabetes and obesity) and GB-5001 (for dementia).
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024-----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer HeeyongLee
Head of R&D EunyoungSeol

General Information
Outstanding Shares: 4,448,452 (As of 7/24/2025)
Fax Number: +82 432706099


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 12, 2025